Navigation Links
Charleston Laboratories, Inc. Phase I Clinical Trial
Date:1/12/2009

Charleston begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108

CHARLESTON, S.C., Jan. 12 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today the initiation of a pharmacokinetic study on its first drug candidate, CL-108. "After many months' development in the lab, resulting in the optimal formulation of this drug, it is ready for testing in man," said Dr. Bernard Schachtel, Chief Medical Officer at Charleston Laboratories. "This Phase I study is being conducted to identify and characterize the release characteristics of CL-108, showing its differences (and similarities) to comparator drugs. We expect that the in-vivo results from this study will confirm the in-vitro results on CL-108, which can be advanced to the Phase III efficacy and safety trial we discussed with the FDA at our Pre-IND Meeting."

In fact, Dr. Schachtel added, "When the results of the Phase I study are available (in early 2009), Charleston Labs will be ready to test the efficacy and safety of CL-108 in patients with acute pain. Charleston Labs' Phase III study on CL-108 is already in the planning stages," he said. "Clinical investigators have been selected at major U.S. universities to conduct this large study beginning in 2009."

"We are looking forward to achieving the expected results of our fast dissolving low dose anti-emetic," said Paul Bosse, Chief Executive Officer at Charleston Laboratories. "CL-108 is the first of many planned therapeutic products Charleston is advancing into clinical studies." Reaching this exciting milestone is a testament of perseverance and dedication by the entire Charleston team."

All clinical studies for Charleston Laboratories are being overseen by SRC, Inc., a contract research organization base
'/>"/>

SOURCE Charleston Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Doug Flutie, Jr. Foundation Grants NAA $10,000 for Burbacher/Charleston Study
2. The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients
3. Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
7. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
8. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
9. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
10. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... ... August 01, 2015 , ... Have you ever wondered what “Karma” really means? Does it ... word “Karma.” , Vedic tradition, which gave birth to Hinduism, is one of the ... central concepts of this tradition. According to the wisdom of this heritage, Karma is a ...
(Date:8/1/2015)... ... ... Calvary Hospital today announced that it is embarking on a yearlong restoration ... bring this Torah – dating from 1880 – back to kosher status, so that ... Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan to Calvary ...
(Date:8/1/2015)... ... 2015 , ... Brig and Lita Hart, icons of the network marketing industry ... Home mission with the HOPE Movement of EvolvHealth. In what has been a long-term ... agreed to join their missions of purpose together to change the course of the ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, ... who are thought to have been behind the attack on Anthem Inc. which resulted ... zero day exploits, watering hole attacks and spear phishing campaigns. , For ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4
... May 31 Telik, Inc. (Nasdaq: TELK ... of the American Society of Clinical Oncology (ASCO) in ... randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination ... second-line therapy in platinum refractory or resistant ovarian cancer. ...
... - New research quantifies the precise effects of environmental ... studies being presented this week during Digestive Disease Week ... that the environment and alcohol intake can affect GI ... future research. DDW is the largest international gathering of ...
... breast tumor treatments called ,exciting, , , SUNDAY, May 31 ... nice to be anywhere," singer and actress Olivia Newton-John, ... one of the world,s largest gatherings of cancer specialists ... news briefing on advances and insights in breast and ...
... seek alternatives to SSRIs for hot flashes, studies suggest ... antidepressants that many breast cancer survivors use to dampen ... boost the odds of the disease,s return, new research ... the American Society of Clinical Oncology,s annual meeting, in ...
... cyclists to start San Francisco-to-Los Angeles ride May 31SAN ... 2,150 bicyclists from 41 states and 14 nations will ... route to Los Angeles as participants in the colorful ... 545-mile trek is expected to raise $10.5 million to ...
... Red technology (NIR) delivers revolutionary pain free hair removal. ... UK to offer genuine groundbreaking hair removal laser technology ... 31 Transform, the UK,s largest group of plastic ... of the first in the UK to install the ...
Cached Medicine News:Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 2Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 3Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 4Health News:To what extent can environmental pollutants and alcohol affect GI health? 2Health News:To what extent can environmental pollutants and alcohol affect GI health? 3Health News:New Insights, Inroads Against Breast, Ovarian Cancers 2Health News:New Insights, Inroads Against Breast, Ovarian Cancers 3Health News:New Insights, Inroads Against Breast, Ovarian Cancers 4Health News:New Insights, Inroads Against Breast, Ovarian Cancers 5Health News:Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer 2Health News:Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 4Health News:Pain-Free, Hair-Free System Set to Transform Hair Removal 2Health News:Pain-Free, Hair-Free System Set to Transform Hair Removal 3
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... Reports Significantly More Patients Treated,with Taxotere(R)-Based ... CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- ... maintained long-term efficacy as a treatment ... to the three-year updated results of ...
... - Schering-Plough Corp. announced results,from a Phase ... (pegylated liposomal doxorubicin hydrochloride),significantly prolonged time to ... with infrequent and manageable clinical,toxicity after first-line ... 43rd Annual Meeting of the American Society ...
Cached Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: